---
schema_version: "secwatch.filing_event.v1"
accession: "0001628908-23-000061"
form_type: "8-K"
ticker: "EVH"
cik: "0001628908"
company_name: "Evolent Health, Inc."
filed_at: "2023-05-03T23:59:59+00:00"
generated_at: "2026-06-16T01:08:09.268125+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Evolent Health Q1 rev. $427.7M (+44%), adj. EBITDA $50.5M; names new COO

## Summary
- Revenue $427.7M (+44% YoY); net loss $26.3M; Adj. EBITDA $50.5M (11.8% margin).
- Total Lives on Platform 65.6M, up from 17.9M YoY; average unique members 41.3M.
- Expanded oncology solution with Centene; national payer agreement with AMSURG for surgical management.
- COO Steve Tutewohl departing July 3; Emily Rafferty appointed COO effective same date.
- CEO Seth Blackley expressed confidence in 2023 outlook and 2024 EBITDA run-rate target.

## SEC filing metadata
- accession: 0001628908-23-000061
- form_type: 8-K
- ticker: EVH
- cik: 0001628908
- company_name: Evolent Health, Inc.
- filed_at: 2023-05-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628908/000162890823000061/0001628908-23-000061-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628908/000162890823000061/evh-20230503.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628908-23-000061
- JSON: https://secwatch.observer/filing/0001628908-23-000061.json
- Plain text: https://secwatch.observer/filing/0001628908-23-000061.txt

## Key facts
- Earnings Releases
  Evolent Health, Inc. reported the quarter ended March 31, 2023 results: revenue $427.7 million, net income Net loss attributable to common shareholders of Evolent Health, Inc. of $26.3 million.
  - Period: the quarter ended March 31, 2023
  - Revenue: $427.7 million
  - Net income: Net loss attributable to common shareholders of Evolent Health, Inc. of $26.3 million
  - Result: reported results
  source text: to payers and providers, today announced financial results for the quarter ended March 31, 2023. Highlights from the first quarter 2023 announcement include: • Revenue of $427.7 million, an increase of $130.6 million, or 44.0%, from the three months ended March 31, 2022. • Net loss attributable to common shareholders of Evolent Health, Inc. of $26.3 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1628908/000162890823000061/0001628908-23-000061-index.htm
- Executive change
  Steve Tutewohl departed as Chief Operating Officer at Evolent Health, Inc..
  - Action: departure
  - Role: Chief Operating Officer
  source text: In connection with organizational restructuring, the Company is announcing the departure of Steve Tutewohl, Chief Operating Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1628908/000162890823000061/0001628908-23-000061-index.htm
- Executive change
  Emily Rafferty was appointed as Chief Operating Officer at Evolent Health, Inc..
  - Action: appointed
  - Role: Chief Operating Officer
  source text: On May 3, 2023, the Company’s Board of Directors appointed Emily Rafferty to serve as the Company’s Chief Operating Officer, effective July 3, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1628908/000162890823000061/0001628908-23-000061-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.